Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 547960, 8 pages
http://dx.doi.org/10.1155/2015/547960
Research Article

Comparison of United States and Canadian Glaucoma Medication Costs and Price Change from 2006 to 2013

1Department of Ophthalmology & Vision Sciences, University of Toronto, 340 College Street, Suite 400, Toronto, ON, Canada M5T 3A9
2Toronto Western Hospital, East Wing 6-405, Bathurst Street, Toronto, ON, Canada M5T 2S8
3Kensington Eye Institute, 340 College Street, Suite 400, Toronto, ON, Canada M5T 3A9

Received 9 December 2014; Accepted 5 March 2015

Academic Editor: Terri L. Young

Copyright © 2015 Matthew B. Schlenker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Quigley and A. T. Broman, “The number of people with glaucoma worldwide in 2010 and 2020,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 262–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. B. Rein, P. Zhang, K. E. Wirth et al., “The economic burden of major adult visual disorders in the United States,” Archives of Ophthalmology, vol. 124, no. 12, pp. 1754–1760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. P. Lee, J. G. Walt, J. J. Doyle et al., “A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma,” Archives of Ophthalmology, vol. 124, no. 1, pp. 12–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Friedman, S. R. Hahn, L. Gelb et al., “Doctor-patient communication, health-related beliefs, and adherence in glaucoma: results from the glaucoma adherence and persistency study,” Ophthalmology, vol. 115, no. 8, pp. 1320.e3–1327.e3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Tsai, “Medication adherence in glaucoma: approaches for optimizing patient compliance,” Current Opinion in Ophthalmology, vol. 17, no. 2, pp. 190–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Sleath, A. L. Robin, D. Covert, J. E. Byrd, G. Tudor, and B. Svarstad, “Patient-reported behavior and problems in using glaucoma medications,” Ophthalmology, vol. 113, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. W. C. Stewart, R. P. Chorak, H. H. Hunt, and G. Sethuraman, “Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head,” The American Journal of Ophthalmology, vol. 116, no. 2, pp. 176–181, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Creese, “WHO/HAI project on medicine prices and availability 2011,” Working Paper 5: Sales Taxes on Medicines, 2011, http://www.haiweb.org/medicineprices/05062011/Taxes%20final%20May2011.pdf. View at Google Scholar
  9. Sales taxes in the United States: Wikipedia, The Free Encyclopedia, Wikimedia Foundation, Inc., 2014, http://en.wikipedia.org/wiki/Sales_taxes_in_the_United_States.
  10. R. G. Fiscella, A. Green, D. H. Patuszynski, and J. Wilensky, “Medical therapy cost considerations for glaucoma,” The American Journal of Ophthalmology, vol. 136, no. 1, pp. 18–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. N. R. Rylander and S. D. Vold, “Cost analysis of glaucoma medications,” American Journal of Ophthalmology, vol. 145, no. 1, pp. 106–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Lee and C. M. L. Hutnik, “Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan,” Canadian Journal of Ophthalmology, vol. 41, no. 4, pp. 449–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Iordanous, J. S. Kent, C. M. L. Hutnik, and M. S. Malvankar-Mehta, “Projected cost comparison of trabectome, istent, and endoscopic cyclophotocoagulation versus glaucoma medication in the ontario health insurance plan,” Journal of Glaucoma, vol. 23, no. 2, pp. e112–e118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Platt, G. Reardon, and E. Mozaffari, “Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size,” The American Journal of Ophthalmology, vol. 137, no. 1, supplement, pp. S17–S23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Monthly and Annual Average Exchange Rates, Bank of Canada, Ottawa, Canada, 2014, http://www.bankofcanada.ca/rates/exchange/exchange-rates-in-pdf/.
  16. Drugs Funded by Ontario Drug Benefit (ODB) Program, Ontario Ministry of Health and Long-term Care, Ottawa, Canada, 2014, http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx.
  17. N. Thomson, Red Book 2006: Pharmacy's Fundamental Reference, PDR Network, Portland, Ore, USA, 2006.
  18. Red Book: A Comprehensive, Consistent Drug Pricing Resource, Truven Health Analytics, Greenwood Village, Colo, USA, 2013, http://micromedex.com/redbook.
  19. Inflation Calculator: Bank of Canada, 2014, http://www.bankofcanada.ca/rates/related/inflation-calculator/.
  20. US Inflation Calculator, 2014, http://www.usinflationcalculator.com/.
  21. Comparing Pharmacy Dispensing Fees, MERITtalk, 2011, http://www.meritcanada.ca/meritcms/docs/merittalk/MeritTalk_2011_MayJun.pdf.
  22. Medicine use and shifting costs of healthcare, IMS Institute for Healthcare Informatics, Parsippany, NJ, USA, 2014, http://pharmaceuticalcommerce.com/latest_news?articleid=26868.
  23. Frequently Asked Questions, Patented Medicine Prices Review Board, Ottawa, Canada, 2014, http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1556&mid=1406.
  24. D. W. Light and J. R. Lexchin, “Pharmaceutical research and development: what do we get for all that money?” British Medical Journal, vol. 345, Article ID e4348, 2012. View at Publisher · View at Google Scholar
  25. M. Rovere and B. Skinner, “Ontario's generic drug pricing debacle: price fixing is not the answer,” Fraser Forum, 2010, http://www.fraserinstitute.org/uploadedFiles/fraser-ca/Content/research-news/research/articles/ontarios-generic-drug-pricing-debacle.pdf. View at Google Scholar
  26. Patent Medicine Prices Review Board, Generic Drugs in Canada: Price Trends and International Price Comparisons, 2007, Patent Medicine Prices Review Board, Ottawa, Canada, 2010.
  27. M. R. Law and J. Kratzer, “The road to competitive generic drug prices in Canada,” Canadian Medical Association Journal, vol. 185, no. 13, pp. 1141–1144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Reforming Ontario's Drug System, Ontario Government, Toronto, Canada, 2010, http://news.ontario.ca/mohltc/en/2010/04/reforming-ontarios-drug-system.html.
  29. A. Anis, S. Harvard, and C. Marra, “Ontario's plunging price-caps on generics: deeper dives may drown some drugs,” Open Medicine, vol. 5, no. 3, pp. e149–e152, 2011. View at Google Scholar
  30. The Patented Medicine Prices Review Board, Generic Drugs in Canada, The Patented Medicine Prices Review Board, Ottawa, Canada, 2013, http://www.pmprb-cepmb.gc.ca/CMFiles/NPDUIS/2013-GenReport/PMPRB_NPDUIS_GenericDrugs2013_2014-12_EN.pdf.
  31. Z. N. Mammo, J. G. Flanagan, D. F. James, and G. E. Trope, “Generic versus brand-name North American topical glaucoma drops,” Canadian Journal of Ophthalmology, vol. 47, no. 1, pp. 55–61, 2012. View at Publisher · View at Google Scholar · View at Scopus